Trial · NCT02982668
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Rate of patients with death or major disability (modified Rankin scale score ≥3) | 3 months after enrollment | modified Rankin scale score, with score ranging from 0 (normal) to 6 (death), was used to evaluate the functional outcomes after stroke. |
| Secondary | Mortality (rate of patients with death) | 3 months after enrollment | Rate of patients with death |
| Secondary | The scores of National Institute of Health stroke scale | 7 days after enrollment | National Institute of Health stroke scale, with scores ranging from 0 (normal function) to 42 (functional impairment)) was used to evaluate the impairment caused by a stroke. |
| Secondary | Glasgow Coma Scale | 7 days after enrollment | Glasgow Coma Scale, with scores ranging from 3 (no response) to 15 (normal response), was used to grade the conscious state. |
| Secondary | modified Rankin scale | 7 days after enrollment | modified Rankin scale score, with score ranging from 0 (normal) to 6 (death), was used to evaluate the functional outcomes after stroke. |
| Secondary | Barthel index | 7 days after enrollment | The Barthel Index is a scale, with score ranging from 0 to 100 (normal), that measures disability or dependence in activities of daily living in stroke patients |
| Secondary | modified Rankin scale | 3 months after enrollment | modified Rankin scale score, with score ranging from 0 (normal) to 6 (death), was used to evaluate the functional outcomes after stroke. |
| Secondary | Barthel index | 3 months after enrollment | The Barthel Index is a scale, with score ranging from 0 to 100 (normal), that measures disability or dependence in activities of daily living in stroke patients |
| Secondary | The incidence of treatment intolerance | 7 days after enrollment | The intolerance including gastric retention, diarrhea, constipation, gastrointestinal hemorrhage |
| Secondary | The incidence of serious adverse events | 3 months after enrollment | |
| Secondary | The incidence of adverse events That are related to treatment | 3 months after enrollment |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02982668/registered